A PYMNTS Company

China: Vitamin C dispute clashes over U.S. Antitrust Law

By  |  January 29, 2015

A price-fixing fight over a common dietary supplement made mostly by companies in China has set the stage for a US appeals court to consider differences between American competition law and the Chinese government.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Hebei Welcome Pharmaceutical Co. and its state-owned parent, North China Pharmaceutical Group Corp., were required by law to coordinate export prices and volumes, the ministry said in a filing to the US Court of Appeals in Manhattan, which is scheduled to hear the Chinese companies’ request to throw out the verdict on Thursday.

    North China Pharmaceutical Group, a leading Chinese drug maker, said it shouldn’t even be implicated in the case because it had no contact with U.S. vitamin C buyers and didn’t exert day-to-day control over Hebei Welcome. Both companies are based in Shijiazhuang, China

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.